NEUVIOR advances ZYLON™ programme following Innovate UK award
NEUVIOR Pharmaceuticals Ltd has been awarded a feasibility grant from Innovate UK under its Resource Efficiency for Resilience and Sustainability competition, with early lab trials now underway at the BDC. This award is separate to the company’s previous Innovate UK funding.
ZYLON™, developed under an Innovate UK-funded feasibility project (“VIONIX ZERO™ - Bio-Intelligent Materials for Net-Zero Pharmaceutical Manufacturing”), supports early-stage work to explore how pharmaceutical production can become more circular, less wasteful, and lower carbon.
ZYLON™ is NEUVIOR’s commercial programme focused on recovering material from pharmaceutical manufacturing processes and developing smarter, bio-based packaging materials that could replace harder-to-recycle formats.
The award represents an important feasibility-stage validation, providing an initial public proof point for the concept with future customers, partners, and investors.
Varun Cruz, founder of NEUVIOR, said:
ZYLON™ is about turning early-stage ideas into real, testable data. This feasibility work allows us to validate core assumptions in a live lab environment and define a credible path toward more circular pharmaceutical manufacturing.
Following the award, NEUVIOR has moved from a funded concept into early lab execution. Clean-chemistry feasibility trials are currently being conducted at the Biorenewables Development Centre in York, using their pilot-scale, bioprocessing centre for technical support and feasibility trials.
Mark Gronnow, Process Development Team Lead at the BDC, said
The BDC is happy to support NEUVIOR on their development journey of an exciting biobased product range. Being able to rapidly and flexibly support innovators with facilities and resources is one of our specialisms.
These trials are focused on disciplined lab execution and the generation of baseline data, exploring bio-derived inputs and de-risking potential approaches that could underpin more circular pharmaceutical manufacturing systems. The trial will be led by Dr Carlos Bueno Alejo and will conclude on Tuesday April 21.
Dr Carlos Bueno Alejo said
I’m excited to participate in this interesting feasibility project that could have a great impact in how pharmaceutical products are manufactured in a more sustainable way.
The programme supports NEUVIOR’s position as a manufacturing innovation company operating across pharmaceuticals, materials, and sustainability, complementing its existing work in software and AI-led platforms.
The current phase of work is focused on feasibility, prototyping, and early-stage trials, with the aim of informing future development and defining a credible pathway to scale.
About NEUVIOR Pharmaceuticals
NEUVIOR is a UK pharmaceutical group building infrastructure across medicines intelligence, supply, applied research and pharmacy operations. Incorporated in Glasgow in August 2025, NEUVIOR Pharmaceuticals Ltd sits at the intersection of pharmaceutical preparation, wholesale, biotechnology R&D and software-enabled operating systems. In 2025 NEUVIOR secured innovative UK funding for its AI backed generic medication optimisation product PHARMORIS® : a medicines value operating system for health systems. Around PHARMORIS® sits a broader group strategy spanning Rx, labs, pharmacy and future manufacturing adjacencies.
Let's work together
We have worked on 1,500 bio-based projects to date
We have several ways to work with us, including business advisory programmes and self-funded commercial options. We even have the option for you to hire our state-of-the-art laboratory equipment and office space.
